A trial in China could cost half of what it does in the U.S., says the report. With clinical trials accounting for up to two-thirds of the cost of drug development, savings could be substantial.
Five areas evaluated included patient availability, cost-efficiency, expertise, regulatory conditions and infrastructure. India, Russia, Brazil, and the Czech Republic followed behind China.
Five areas evaluated included patient availability, cost-efficiency, expertise, regulatory conditions and infrastructure. India, Russia, Brazil, and the Czech Republic followed behind China.
![Alison Bryant, senior consultant at Antea Group and communications director for the Healthcare Plastics Recycling Council (HPRC), addressed the crowd at the[PACK]out.](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2024/05/Alison_Bryant.6644005a513b0.png?auto=format%2Ccompress&fit=crop&h=167&q=70&w=250)
